CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT

The purpose is to characterize the features of the clinical picture, interferon and immune system status in shigellosis associated with herpesvirus infections in children, and to justify the inclusion of recombinant interferon-a2b (VIFERON®) in the complex treatment program of the disease. Clinical...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	E. N. Simovanyan [verfasserIn] V. B. Denisenko [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2017

Schlagwörter:	шигеллез герпесвирусная инфекция дети рекомбинантный интерферон-2b

Übergeordnetes Werk:	In: Детские инфекции (Москва) - LLC "Diagnostics and Vaccines", 2016, 16(2017), 4, Seite 29-36
Übergeordnetes Werk:	volume:16 ; year:2017 ; number:4 ; pages:29-36

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.22627/2072-8107-2017-16-4-29-36

Katalog-ID:	DOAJ08568659X

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ08568659X
003	DE-627
005	20230503030228.0
007	cr uuu---uuuuu
008	230311s2017 xx \|\|\|\|\|o 00\| \|\|rus c
024	7		\|a 10.22627/2072-8107-2017-16-4-29-36 \|2 doi
035			\|a (DE-627)DOAJ08568659X
035			\|a (DE-599)DOAJ5b25ed849ac8447fa9845779673b297c
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RJ1-570
100	0		\|a E. N. Simovanyan \|e verfasserin \|4 aut
245	1	0	\|a CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT
264		1	\|c 2017
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The purpose is to characterize the features of the clinical picture, interferon and immune system status in shigellosis associated with herpesvirus infections in children, and to justify the inclusion of recombinant interferon-a2b (VIFERON®) in the complex treatment program of the disease. Clinical and immunological examination of 136 patients with shigellosis at the age from 1 to 3 years was carried out. In 65 children the active form of herpesvirus infection was diagnosed, in 20 patients it was absent. Active form of herpesvirus infection developed in children with a burdened premorbid background. These patients showed a violation of the immune response regulation by cellular type (reduction of interferon-g spontaneous and stimulated production, expression of CD119 receptors), the effector stage of the adaptive immune response. Clinically associated shigellosis was characterized by a severe course, a frequent development of complications. Inclusion of recombinant interferon-a2b (VIFERON®) in the complex program of treatment promoted the modulation of the regulatory and effector stages of the immune response. There was a reduction in the duration of the main symptoms of the disease and the stay of patients in the hospital.High efficiency of recombinant interferon-a2b (VIFERON®) application make it possible to recommend the inclusion of this drug in the treatment of shigellosis associated with herpesvirus infection in children.
650		4	\|a шигеллез
650		4	\|a герпесвирусная инфекция
650		4	\|a дети
650		4	\|a рекомбинантный интерферон-2b
653		0	\|a Pediatrics
700	0		\|a V. B. Denisenko \|e verfasserin \|4 aut
773	0	8	\|i In \|t Детские инфекции (Москва) \|d LLC "Diagnostics and Vaccines", 2016 \|g 16(2017), 4, Seite 29-36 \|w (DE-627)1760619124 \|x 20728107 \|7 nnns
773	1	8	\|g volume:16 \|g year:2017 \|g number:4 \|g pages:29-36
856	4	0	\|u https://doi.org/10.22627/2072-8107-2017-16-4-29-36 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/5b25ed849ac8447fa9845779673b297c \|z kostenfrei
856	4	0	\|u https://detinf.elpub.ru/jour/article/view/323 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2072-8107 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 16 \|j 2017 \|e 4 \|h 29-36

Indexfelder

author_variant	e n s ens v b d vbd
matchkey_str	article:20728107:2017----::lnclnimnlgclhrceitcosielsssoitdihepsiuifcinici
hierarchy_sort_str	2017
callnumber-subject-code	RJ
publishDate	2017
allfields	10.22627/2072-8107-2017-16-4-29-36 doi (DE-627)DOAJ08568659X (DE-599)DOAJ5b25ed849ac8447fa9845779673b297c DE-627 ger DE-627 rakwb rus RJ1-570 E. N. Simovanyan verfasserin aut CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The purpose is to characterize the features of the clinical picture, interferon and immune system status in shigellosis associated with herpesvirus infections in children, and to justify the inclusion of recombinant interferon-a2b (VIFERON®) in the complex treatment program of the disease. Clinical and immunological examination of 136 patients with shigellosis at the age from 1 to 3 years was carried out. In 65 children the active form of herpesvirus infection was diagnosed, in 20 patients it was absent. Active form of herpesvirus infection developed in children with a burdened premorbid background. These patients showed a violation of the immune response regulation by cellular type (reduction of interferon-g spontaneous and stimulated production, expression of CD119 receptors), the effector stage of the adaptive immune response. Clinically associated shigellosis was characterized by a severe course, a frequent development of complications. Inclusion of recombinant interferon-a2b (VIFERON®) in the complex program of treatment promoted the modulation of the regulatory and effector stages of the immune response. There was a reduction in the duration of the main symptoms of the disease and the stay of patients in the hospital.High efficiency of recombinant interferon-a2b (VIFERON®) application make it possible to recommend the inclusion of this drug in the treatment of shigellosis associated with herpesvirus infection in children. шигеллез герпесвирусная инфекция дети рекомбинантный интерферон-2b Pediatrics V. B. Denisenko verfasserin aut In Детские инфекции (Москва) LLC "Diagnostics and Vaccines", 2016 16(2017), 4, Seite 29-36 (DE-627)1760619124 20728107 nnns volume:16 year:2017 number:4 pages:29-36 https://doi.org/10.22627/2072-8107-2017-16-4-29-36 kostenfrei https://doaj.org/article/5b25ed849ac8447fa9845779673b297c kostenfrei https://detinf.elpub.ru/jour/article/view/323 kostenfrei https://doaj.org/toc/2072-8107 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2017 4 29-36
spelling	10.22627/2072-8107-2017-16-4-29-36 doi (DE-627)DOAJ08568659X (DE-599)DOAJ5b25ed849ac8447fa9845779673b297c DE-627 ger DE-627 rakwb rus RJ1-570 E. N. Simovanyan verfasserin aut CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The purpose is to characterize the features of the clinical picture, interferon and immune system status in shigellosis associated with herpesvirus infections in children, and to justify the inclusion of recombinant interferon-a2b (VIFERON®) in the complex treatment program of the disease. Clinical and immunological examination of 136 patients with shigellosis at the age from 1 to 3 years was carried out. In 65 children the active form of herpesvirus infection was diagnosed, in 20 patients it was absent. Active form of herpesvirus infection developed in children with a burdened premorbid background. These patients showed a violation of the immune response regulation by cellular type (reduction of interferon-g spontaneous and stimulated production, expression of CD119 receptors), the effector stage of the adaptive immune response. Clinically associated shigellosis was characterized by a severe course, a frequent development of complications. Inclusion of recombinant interferon-a2b (VIFERON®) in the complex program of treatment promoted the modulation of the regulatory and effector stages of the immune response. There was a reduction in the duration of the main symptoms of the disease and the stay of patients in the hospital.High efficiency of recombinant interferon-a2b (VIFERON®) application make it possible to recommend the inclusion of this drug in the treatment of shigellosis associated with herpesvirus infection in children. шигеллез герпесвирусная инфекция дети рекомбинантный интерферон-2b Pediatrics V. B. Denisenko verfasserin aut In Детские инфекции (Москва) LLC "Diagnostics and Vaccines", 2016 16(2017), 4, Seite 29-36 (DE-627)1760619124 20728107 nnns volume:16 year:2017 number:4 pages:29-36 https://doi.org/10.22627/2072-8107-2017-16-4-29-36 kostenfrei https://doaj.org/article/5b25ed849ac8447fa9845779673b297c kostenfrei https://detinf.elpub.ru/jour/article/view/323 kostenfrei https://doaj.org/toc/2072-8107 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2017 4 29-36
allfields_unstemmed	10.22627/2072-8107-2017-16-4-29-36 doi (DE-627)DOAJ08568659X (DE-599)DOAJ5b25ed849ac8447fa9845779673b297c DE-627 ger DE-627 rakwb rus RJ1-570 E. N. Simovanyan verfasserin aut CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The purpose is to characterize the features of the clinical picture, interferon and immune system status in shigellosis associated with herpesvirus infections in children, and to justify the inclusion of recombinant interferon-a2b (VIFERON®) in the complex treatment program of the disease. Clinical and immunological examination of 136 patients with shigellosis at the age from 1 to 3 years was carried out. In 65 children the active form of herpesvirus infection was diagnosed, in 20 patients it was absent. Active form of herpesvirus infection developed in children with a burdened premorbid background. These patients showed a violation of the immune response regulation by cellular type (reduction of interferon-g spontaneous and stimulated production, expression of CD119 receptors), the effector stage of the adaptive immune response. Clinically associated shigellosis was characterized by a severe course, a frequent development of complications. Inclusion of recombinant interferon-a2b (VIFERON®) in the complex program of treatment promoted the modulation of the regulatory and effector stages of the immune response. There was a reduction in the duration of the main symptoms of the disease and the stay of patients in the hospital.High efficiency of recombinant interferon-a2b (VIFERON®) application make it possible to recommend the inclusion of this drug in the treatment of shigellosis associated with herpesvirus infection in children. шигеллез герпесвирусная инфекция дети рекомбинантный интерферон-2b Pediatrics V. B. Denisenko verfasserin aut In Детские инфекции (Москва) LLC "Diagnostics and Vaccines", 2016 16(2017), 4, Seite 29-36 (DE-627)1760619124 20728107 nnns volume:16 year:2017 number:4 pages:29-36 https://doi.org/10.22627/2072-8107-2017-16-4-29-36 kostenfrei https://doaj.org/article/5b25ed849ac8447fa9845779673b297c kostenfrei https://detinf.elpub.ru/jour/article/view/323 kostenfrei https://doaj.org/toc/2072-8107 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2017 4 29-36
allfieldsGer	10.22627/2072-8107-2017-16-4-29-36 doi (DE-627)DOAJ08568659X (DE-599)DOAJ5b25ed849ac8447fa9845779673b297c DE-627 ger DE-627 rakwb rus RJ1-570 E. N. Simovanyan verfasserin aut CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The purpose is to characterize the features of the clinical picture, interferon and immune system status in shigellosis associated with herpesvirus infections in children, and to justify the inclusion of recombinant interferon-a2b (VIFERON®) in the complex treatment program of the disease. Clinical and immunological examination of 136 patients with shigellosis at the age from 1 to 3 years was carried out. In 65 children the active form of herpesvirus infection was diagnosed, in 20 patients it was absent. Active form of herpesvirus infection developed in children with a burdened premorbid background. These patients showed a violation of the immune response regulation by cellular type (reduction of interferon-g spontaneous and stimulated production, expression of CD119 receptors), the effector stage of the adaptive immune response. Clinically associated shigellosis was characterized by a severe course, a frequent development of complications. Inclusion of recombinant interferon-a2b (VIFERON®) in the complex program of treatment promoted the modulation of the regulatory and effector stages of the immune response. There was a reduction in the duration of the main symptoms of the disease and the stay of patients in the hospital.High efficiency of recombinant interferon-a2b (VIFERON®) application make it possible to recommend the inclusion of this drug in the treatment of shigellosis associated with herpesvirus infection in children. шигеллез герпесвирусная инфекция дети рекомбинантный интерферон-2b Pediatrics V. B. Denisenko verfasserin aut In Детские инфекции (Москва) LLC "Diagnostics and Vaccines", 2016 16(2017), 4, Seite 29-36 (DE-627)1760619124 20728107 nnns volume:16 year:2017 number:4 pages:29-36 https://doi.org/10.22627/2072-8107-2017-16-4-29-36 kostenfrei https://doaj.org/article/5b25ed849ac8447fa9845779673b297c kostenfrei https://detinf.elpub.ru/jour/article/view/323 kostenfrei https://doaj.org/toc/2072-8107 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2017 4 29-36
allfieldsSound	10.22627/2072-8107-2017-16-4-29-36 doi (DE-627)DOAJ08568659X (DE-599)DOAJ5b25ed849ac8447fa9845779673b297c DE-627 ger DE-627 rakwb rus RJ1-570 E. N. Simovanyan verfasserin aut CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The purpose is to characterize the features of the clinical picture, interferon and immune system status in shigellosis associated with herpesvirus infections in children, and to justify the inclusion of recombinant interferon-a2b (VIFERON®) in the complex treatment program of the disease. Clinical and immunological examination of 136 patients with shigellosis at the age from 1 to 3 years was carried out. In 65 children the active form of herpesvirus infection was diagnosed, in 20 patients it was absent. Active form of herpesvirus infection developed in children with a burdened premorbid background. These patients showed a violation of the immune response regulation by cellular type (reduction of interferon-g spontaneous and stimulated production, expression of CD119 receptors), the effector stage of the adaptive immune response. Clinically associated shigellosis was characterized by a severe course, a frequent development of complications. Inclusion of recombinant interferon-a2b (VIFERON®) in the complex program of treatment promoted the modulation of the regulatory and effector stages of the immune response. There was a reduction in the duration of the main symptoms of the disease and the stay of patients in the hospital.High efficiency of recombinant interferon-a2b (VIFERON®) application make it possible to recommend the inclusion of this drug in the treatment of shigellosis associated with herpesvirus infection in children. шигеллез герпесвирусная инфекция дети рекомбинантный интерферон-2b Pediatrics V. B. Denisenko verfasserin aut In Детские инфекции (Москва) LLC "Diagnostics and Vaccines", 2016 16(2017), 4, Seite 29-36 (DE-627)1760619124 20728107 nnns volume:16 year:2017 number:4 pages:29-36 https://doi.org/10.22627/2072-8107-2017-16-4-29-36 kostenfrei https://doaj.org/article/5b25ed849ac8447fa9845779673b297c kostenfrei https://detinf.elpub.ru/jour/article/view/323 kostenfrei https://doaj.org/toc/2072-8107 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2017 4 29-36
language	Russian
source	In Детские инфекции (Москва) 16(2017), 4, Seite 29-36 volume:16 year:2017 number:4 pages:29-36
sourceStr	In Детские инфекции (Москва) 16(2017), 4, Seite 29-36 volume:16 year:2017 number:4 pages:29-36
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	шигеллез герпесвирусная инфекция дети рекомбинантный интерферон-2b Pediatrics
isfreeaccess_bool	true
container_title	Детские инфекции (Москва)
authorswithroles_txt_mv	E. N. Simovanyan @@aut@@ V. B. Denisenko @@aut@@
publishDateDaySort_date	2017-01-01T00:00:00Z
hierarchy_top_id	1760619124
id	DOAJ08568659X
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ08568659X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503030228.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2017 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.22627/2072-8107-2017-16-4-29-36</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ08568659X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5b25ed849ac8447fa9845779673b297c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RJ1-570</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E. N. Simovanyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The purpose is to characterize the features of the clinical picture, interferon and immune system status in shigellosis associated with herpesvirus infections in children, and to justify the inclusion of recombinant interferon-a2b (VIFERON®) in the complex treatment program of the disease. Clinical and immunological examination of 136 patients with shigellosis at the age from 1 to 3 years was carried out. In 65 children the active form of herpesvirus infection was diagnosed, in 20 patients it was absent. Active form of herpesvirus infection developed in children with a burdened premorbid background. These patients showed a violation of the immune response regulation by cellular type (reduction of interferon-g spontaneous and stimulated production, expression of CD119 receptors), the effector stage of the adaptive immune response. Clinically associated shigellosis was characterized by a severe course, a frequent development of complications. Inclusion of recombinant interferon-a2b (VIFERON®) in the complex program of treatment promoted the modulation of the regulatory and effector stages of the immune response. There was a reduction in the duration of the main symptoms of the disease and the stay of patients in the hospital.High efficiency of recombinant interferon-a2b (VIFERON®) application make it possible to recommend the inclusion of this drug in the treatment of shigellosis associated with herpesvirus infection in children.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">шигеллез</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">герпесвирусная инфекция</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">дети</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">рекомбинантный интерферон-2b</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pediatrics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. B. Denisenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Детские инфекции (Москва)</subfield><subfield code="d">LLC "Diagnostics and Vaccines", 2016</subfield><subfield code="g">16(2017), 4, Seite 29-36</subfield><subfield code="w">(DE-627)1760619124</subfield><subfield code="x">20728107</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:29-36</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.22627/2072-8107-2017-16-4-29-36</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5b25ed849ac8447fa9845779673b297c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://detinf.elpub.ru/jour/article/view/323</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-8107</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2017</subfield><subfield code="e">4</subfield><subfield code="h">29-36</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	E. N. Simovanyan
spellingShingle	E. N. Simovanyan misc RJ1-570 misc шигеллез misc герпесвирусная инфекция misc дети misc рекомбинантный интерферон-2b misc Pediatrics CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT
authorStr	E. N. Simovanyan
ppnlink_with_tag_str_mv	@@773@@(DE-627)1760619124
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	DOAJ
remote_str	true
callnumber-label	RJ1-570
illustrated	Not Illustrated
issn	20728107
topic_title	RJ1-570 CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT шигеллез герпесвирусная инфекция дети рекомбинантный интерферон-2b
topic	misc RJ1-570 misc шигеллез misc герпесвирусная инфекция misc дети misc рекомбинантный интерферон-2b misc Pediatrics
topic_unstemmed	misc RJ1-570 misc шигеллез misc герпесвирусная инфекция misc дети misc рекомбинантный интерферон-2b misc Pediatrics
topic_browse	misc RJ1-570 misc шигеллез misc герпесвирусная инфекция misc дети misc рекомбинантный интерферон-2b misc Pediatrics
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Детские инфекции (Москва)
hierarchy_parent_id	1760619124
hierarchy_top_title	Детские инфекции (Москва)
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1760619124
title	CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT
ctrlnum	(DE-627)DOAJ08568659X (DE-599)DOAJ5b25ed849ac8447fa9845779673b297c
title_full	CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT
author_sort	E. N. Simovanyan
journal	Детские инфекции (Москва)
journalStr	Детские инфекции (Москва)
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2017
contenttype_str_mv	txt
container_start_page	29
author_browse	E. N. Simovanyan V. B. Denisenko
container_volume	16
class	RJ1-570
format_se	Elektronische Aufsätze
author-letter	E. N. Simovanyan
doi_str_mv	10.22627/2072-8107-2017-16-4-29-36
author2-role	verfasserin
title_sort	clinical and immunological characteristics of shigellosis associated with herpesvirus infections in children: a clinic, diagnosis and treatment
callnumber	RJ1-570
title_auth	CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT
abstract	The purpose is to characterize the features of the clinical picture, interferon and immune system status in shigellosis associated with herpesvirus infections in children, and to justify the inclusion of recombinant interferon-a2b (VIFERON®) in the complex treatment program of the disease. Clinical and immunological examination of 136 patients with shigellosis at the age from 1 to 3 years was carried out. In 65 children the active form of herpesvirus infection was diagnosed, in 20 patients it was absent. Active form of herpesvirus infection developed in children with a burdened premorbid background. These patients showed a violation of the immune response regulation by cellular type (reduction of interferon-g spontaneous and stimulated production, expression of CD119 receptors), the effector stage of the adaptive immune response. Clinically associated shigellosis was characterized by a severe course, a frequent development of complications. Inclusion of recombinant interferon-a2b (VIFERON®) in the complex program of treatment promoted the modulation of the regulatory and effector stages of the immune response. There was a reduction in the duration of the main symptoms of the disease and the stay of patients in the hospital.High efficiency of recombinant interferon-a2b (VIFERON®) application make it possible to recommend the inclusion of this drug in the treatment of shigellosis associated with herpesvirus infection in children.
abstractGer	The purpose is to characterize the features of the clinical picture, interferon and immune system status in shigellosis associated with herpesvirus infections in children, and to justify the inclusion of recombinant interferon-a2b (VIFERON®) in the complex treatment program of the disease. Clinical and immunological examination of 136 patients with shigellosis at the age from 1 to 3 years was carried out. In 65 children the active form of herpesvirus infection was diagnosed, in 20 patients it was absent. Active form of herpesvirus infection developed in children with a burdened premorbid background. These patients showed a violation of the immune response regulation by cellular type (reduction of interferon-g spontaneous and stimulated production, expression of CD119 receptors), the effector stage of the adaptive immune response. Clinically associated shigellosis was characterized by a severe course, a frequent development of complications. Inclusion of recombinant interferon-a2b (VIFERON®) in the complex program of treatment promoted the modulation of the regulatory and effector stages of the immune response. There was a reduction in the duration of the main symptoms of the disease and the stay of patients in the hospital.High efficiency of recombinant interferon-a2b (VIFERON®) application make it possible to recommend the inclusion of this drug in the treatment of shigellosis associated with herpesvirus infection in children.
abstract_unstemmed	The purpose is to characterize the features of the clinical picture, interferon and immune system status in shigellosis associated with herpesvirus infections in children, and to justify the inclusion of recombinant interferon-a2b (VIFERON®) in the complex treatment program of the disease. Clinical and immunological examination of 136 patients with shigellosis at the age from 1 to 3 years was carried out. In 65 children the active form of herpesvirus infection was diagnosed, in 20 patients it was absent. Active form of herpesvirus infection developed in children with a burdened premorbid background. These patients showed a violation of the immune response regulation by cellular type (reduction of interferon-g spontaneous and stimulated production, expression of CD119 receptors), the effector stage of the adaptive immune response. Clinically associated shigellosis was characterized by a severe course, a frequent development of complications. Inclusion of recombinant interferon-a2b (VIFERON®) in the complex program of treatment promoted the modulation of the regulatory and effector stages of the immune response. There was a reduction in the duration of the main symptoms of the disease and the stay of patients in the hospital.High efficiency of recombinant interferon-a2b (VIFERON®) application make it possible to recommend the inclusion of this drug in the treatment of shigellosis associated with herpesvirus infection in children.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	4
title_short	CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT
url	https://doi.org/10.22627/2072-8107-2017-16-4-29-36 https://doaj.org/article/5b25ed849ac8447fa9845779673b297c https://detinf.elpub.ru/jour/article/view/323 https://doaj.org/toc/2072-8107
remote_bool	true
author2	V. B. Denisenko
author2Str	V. B. Denisenko
ppnlink	1760619124
callnumber-subject	RJ - Pediatrics
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.22627/2072-8107-2017-16-4-29-36
callnumber-a	RJ1-570
up_date	2024-07-03T16:15:40.503Z
_version_	1803575194294419456
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ08568659X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503030228.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2017 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.22627/2072-8107-2017-16-4-29-36</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ08568659X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5b25ed849ac8447fa9845779673b297c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RJ1-570</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">E. N. Simovanyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The purpose is to characterize the features of the clinical picture, interferon and immune system status in shigellosis associated with herpesvirus infections in children, and to justify the inclusion of recombinant interferon-a2b (VIFERON®) in the complex treatment program of the disease. Clinical and immunological examination of 136 patients with shigellosis at the age from 1 to 3 years was carried out. In 65 children the active form of herpesvirus infection was diagnosed, in 20 patients it was absent. Active form of herpesvirus infection developed in children with a burdened premorbid background. These patients showed a violation of the immune response regulation by cellular type (reduction of interferon-g spontaneous and stimulated production, expression of CD119 receptors), the effector stage of the adaptive immune response. Clinically associated shigellosis was characterized by a severe course, a frequent development of complications. Inclusion of recombinant interferon-a2b (VIFERON®) in the complex program of treatment promoted the modulation of the regulatory and effector stages of the immune response. There was a reduction in the duration of the main symptoms of the disease and the stay of patients in the hospital.High efficiency of recombinant interferon-a2b (VIFERON®) application make it possible to recommend the inclusion of this drug in the treatment of shigellosis associated with herpesvirus infection in children.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">шигеллез</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">герпесвирусная инфекция</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">дети</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">рекомбинантный интерферон-2b</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pediatrics</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V. B. Denisenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Детские инфекции (Москва)</subfield><subfield code="d">LLC "Diagnostics and Vaccines", 2016</subfield><subfield code="g">16(2017), 4, Seite 29-36</subfield><subfield code="w">(DE-627)1760619124</subfield><subfield code="x">20728107</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:29-36</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.22627/2072-8107-2017-16-4-29-36</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5b25ed849ac8447fa9845779673b297c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://detinf.elpub.ru/jour/article/view/323</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-8107</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2017</subfield><subfield code="e">4</subfield><subfield code="h">29-36</subfield></datafield></record></collection>
score	7.3992662

Nicht das Richtige dabei?

Schreiben Sie uns!

CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF SHIGELLOSIS ASSOCIATED WITH HERPESVIRUS INFECTIONS IN CHILDREN: A CLINIC, DIAGNOSIS AND TREATMENT

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?